This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements relating to the number of platelets treated by the AKH using the INTERCEPT Blood System, potential growth in the use of the INTERCEPT Blood System the potential influence of the AKH over blood safety technology decisions in Austria and Europe. These forward-looking statements are based upon Cerus’ current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with demand for the INTERCEPT Blood System, including the risk that Cerus may not be able to maintain its supply agreement with the AKH, risks associated with Cerus’ ability to achieve broader market acceptance of its INTERCEPT Blood System products, adverse decisions or actions by regulatory agencies including those of Austria, and other risks detailed in the Cerus' filings with, the Securities and Exchange Commission (SEC), including in Cerus' annual report on Form 10-K for the year ended December 31, 2011, filed with the SEC on March 5, 2012. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Cerus does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.
Cerus Corporation (NASDAQ: CERS) announced today that it has signed a two-year agreement with the General Hospital of Vienna (AKH) to supply the INTERCEPT Blood System for platelets. Cerus understands that the AKH plans to use INTERCEPT to treat the approximately 6000 platelet units it produces each year, and has already implemented the INTERCEPT process into their routine production. “We are honored that the AKH has chosen INTERCEPT as their pathogen inactivation technology for platelets,” said Caspar Hogeboom, president of Cerus Europe. “The AKH has a long tradition of providing the highest standards of care for its patients, and we believe their practices have influence throughout Austria and the surrounding European region.” ABOUT GENERAL HOSPITAL OF VIENNA From: http://www.meduniwien.ac.at/homepage/service/vienna-general-hospital-akh/en/The General Hospital of Vienna (AKH) looks back on more than 300 years of history. The original "Home for the Poor and Invalid" has developed into one of the most modern and advanced hospitals in Europe. With more than 30 university clinics and clinical institutes, the AKH guarantees extremely high standards and innovative technologies in all medical fields. At the AKH, patient care, instruction and research have been laid down as inseparable and equal elements. The people are always at the centre of the AKH’s tasks and objectives. See http://www.akhwien.at for more information. ABOUT CERUS Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for more information. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.